News

Altimmune's Upcoming Conferences: Key Insights for Investors

Altimmune's Upcoming Conferences: Key Insights for Investors

Altimmune's Participation in Key Investor Conferences

GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company focused on developing advanced therapeutics for liver and cardiometabolic issues, has recently shared exciting news with investors. Members of the management team will engage with investors at notable upcoming conferences, presenting an excellent opportunity for stakeholders to connect and learn more about the company's innovative approaches.

Conference Details

Stifel 2025 Healthcare Conference

Scheduled for Wednesday, November 12, 2025, Altimmune will host a fireside chat at 10:00 a.m. ET. This session promises to provide valuable insights into the company’s strategic initiatives and advances in treatment options.

Jefferies Global Healthcare Conference

On Thursday, November 20, 2025, Altimmune will participate in another significant event, with a fireside chat arranged for 9:30 a.m. GMT. Both sessions highlight the company's commitment to transparency and investor engagement.

Webcast Availability

For those interested in following along, the sessions will be available via webcast. Viewers can find the links on the Events section of the Altimmune website, ensuring that anyone interested in the developments can access the discussions live.

About Altimmune

Altimmune has made significant strides as a clinical-stage biopharmaceutical firm, focusing on groundbreaking peptide-based therapies that target liver-related and cardiometabolic diseases. Their lead candidate, pemvidutide, is a dual receptor agonist that holds promise for treating metabolic dysfunction-associated steatohepatitis (MASH), among other conditions.

In an era where metabolic disorders are on the rise, the work of Altimmune is particularly crucial. Their focus on addressing conditions like alcohol use disorder and alcohol-associated liver disease positions them as innovators in a challenging healthcare landscape.

Investor Engagement and Outlook

Altimmune's proactive approach to investor relations is commendable. By participating in key conferences, they are not just sharing their journey but actively involving their stakeholders in the conversation about future growth and development. The company's transparency and willingness to engage with investors signal a promising path ahead.

Keeping an eye on the developments from these conferences will be valuable for investors looking to understand more about the company’s future. The discussions are expected to cover not only the current state of their projects but also the long-term vision that drives Altimmune's innovations.

Engaging with Altimmune

Staying connected with Altimmune is essential for investors enthusiastic about the ever-evolving pharmaceutical landscape. The company encourages stakeholders to follow them on social media platforms, including LinkedIn and X, for the latest updates and insights into their ongoing projects.

Frequently Asked Questions

What conferences will Altimmune be attending?

Altimmune will attend the Stifel 2025 Healthcare Conference and the Jefferies Global Healthcare Conference.

When is the Stifel 2025 Healthcare Conference?

The Stifel 2025 Healthcare Conference is scheduled for November 12, 2025.

What is pemvidutide?

Pemvidutide is Altimmune's lead product candidate designed to treat liver diseases, including metabolic dysfunction-associated steatohepatitis.

How can I follow Altimmune's updates?

You can follow Altimmune on LinkedIn and X for the latest news and updates on their developments.

How does Altimmune engage with investors?

Altimmune actively participates in investor conferences and hosts webcasts to engage with stakeholders and share insights about their progress and future plans.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles